A Randomized Controlled Trial of Combined Aerobic Exercise, Constraint-Induced Movement Therapy, and Dialectical Behavioural Therapy on Speed-accuracy trade-off, Cognition, Serum BDNF, and Quality of Life of Stroke Survivors with Post-Stroke Cognitive Impairment (ACD-Stroke Trial)

A Randomized Controlled Trial of Combined Aerobic Exercise, Constraint-Induced Movement Therapy, and Dialectical Behavioural Therapy on Speed–Accuracy Trade-Off, Cognitive Function, Serum Brain-Derived Neurotrophic Factor, and Quality of Life in Stroke Survivors with Post-Stroke Cognitive Impairment (ACD-Stroke Trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202602772956434

Enrollment

100

Registered

2026-02-10

Start date

2026-02-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Injury, Occupational Diseases, Poisoning Nervous System Diseases

Interventions

Neurodevelopmental Therapy

Aerobic Exercise plus Dialectical Behavioural Therapy

Constraint Induced Movement Therapy plus Dialectical Behavioural Therapy

Aerobic Exercise plus Constraint Induced Movement Therapy plus Dialectical Behavioural Therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Adults aged 18 years and above • Clinically confirmed first-ever unilateral ischemic or hemorrhagic stroke • Stroke onset = 3 months prior to enrolment (chronic stroke phase) • Presence of post-stroke cognitive impairment (PSCI) defined by a Mini-Addenbrooke’s Cognitive Examination-III (mACE-III) score =14 and <21 • Fugl-Meyer Assessment–Upper Extremity (FMA-UE) score =20 • Medically stable and cleared by a physician to participate in moderate-intensity exercise • Ability to ambulate independently (Functional Ambulation Category =4) • Ability to follow simple instructions and participate in therapy sessions • Willingness to provide written informed consent

Exclusion criteria

Exclusion criteria: • Severe cognitive impairment (mACE-III score <14) • History of other major neurological conditions (e.g., dementia, Parkinson’s disease, traumatic brain injury) • Severe psychiatric disorders or acute psychological instability • Unstable cardiovascular disease or other contraindications to moderate-intensity exercise • Severe musculoskeletal conditions limiting upper-limb movement • Severe aphasia, neglect, or sensory deficits preventing task comprehension • Participation in another structured rehabilitation or psychotherapy trial during the study period • Any medical condition judged by the investigator to compromise participant safety or protocol adherence

Design outcomes

Primary

Measure	Time frame
Speed–accuracy trade-off measured as the Index of Performance (IP) derived from a standardized Fitts’ Law reaching task.	—

Secondary

Measure	Time frame
Upper limb motor function measured using the Fugl-Meyer Assessment – Upper Extremity (FMA-UE).;Global cognitive function measured using the Addenbrooke’s Cognitive Examination–III (ACE-III).;Serum Brain-Derived Neurotrophic Factor (BDNF) concentration measured using ELISA.;Health-related quality of life measured using the Stroke-Specific Quality of Life Scale (SS-QoL).	—

Countries

Nigeria

Contacts

Public ContactYunusa Usman Mahmoud

Student

abusuhailpt@yahoo.com+2347036922803

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 10, 2026